Clinical Trial

Palm Stimulator Use During Peripheral Venous Catheterization

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Purpose: The purpose of this study is to evaluate the effectiveness of a "Palm Stimulator" (a handheld device with blunt protrusions) in reducing pain, fear, and anxiety during peripheral venous catheterization (IV insertion) in adult cancer patients receiving chemotherapy. Methods: This is a randomized controlled clinical trial. Participants will be randomly assigned to either the Experimental Group or the Control Group. Experimental Group: During the IV insertion process, patients will hold and squeeze the Palm Stimulator in the palm of their non-procedural hand. The device is designed to provide intense tactile (touch) stimulation based on the "Gate Control Theory." Control Group: Patients will receive the standard routine care for IV insertion without any additional intervention. Data Collection: Pain intensity will be measured using the Visual Analog Scale (VAS), while fear and anxiety levels will be assessed through VAS scales before and after the procedure. Patient satisfaction with the device will also be recorded. Expected Outcome: The investigators hypothesize that the use of the Palm Stimulator will significantly decrease procedural pain and fear while increasing patient satisfaction compared to standard care. This study aims to provide a low-cost, non-pharmacological, and easy-to-use tool for oncology nurses to improve patient comfort during invasive procedures.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-28.
Trial Details
NCT Number NCT07387497
Lead Sponsor Zeliha CENGİZ
Conditions Procedural Pain, Cancer, Fear Needles, Anxiety, Catheterization, Peripheral Venous
Enrollment 90 participants
Start Date 2026-02-20
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-06